Edition:
United Kingdom

Adverum Biotechnologies Provides 2018 Outlook


Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES 2018 OUTLOOK.ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017..ADVERUM BIOTECHNOLOGIES INC - CURRENT CASH POSITION IS EXPECTED TO FUND THREE LEAD GENE THERAPY PROGRAMS THROUGH END OF 2019.ADVERUM - PLAN TO SUBMIT 2 INVESTIGATIONAL NDA WITH FDA IN H2 2018, FOR ADVM-022 IN WET AMD, ADVM-053 IN HEREDITARY ANGIOEDEMA. 

Company Quote

9.29
0.0 +0.00%
8:28pm BST